SCHEMBL4918105

SCHEMBL4918105

Cc1ccccc1N1C(=O)C(=CC=Cc2ccccc2)SC1=S

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.61
MEN1 O00255 7/20 0.61
KMT2A Q03164 7/20 0.61
ALDH1A1 P00352 6/20 0.61
HTT P42858 4/20 0.61
NPC1 O15118 3/20 0.61
LMNA P02545 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
POLB P06746 2/20 0.61
TDP1 Q9NUW8 2/20 0.61
PTPN1 P18031 1/20 0.61
PSMD14 O00487 1/20 0.61
ALPG P10696 1/20 0.61
THRB P10828 1/20 0.61
PKM P14618 1/20 0.61
RECQL P46063 1/20 0.61
RAB9A P51151 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
MAPK1 P28482 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30014988 1.00 MAPT (0.61) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL4918099 1.00 MAPT (0.61) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL14213563 0.83 MAPT (0.79) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL14213564 0.78 MAPT (0.78) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL14213565 0.77 MAPT (0.70) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL6738029 0.76 MAPT (1.00) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL1101968 0.75 MAPT (0.73) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL8211219 0.75 MAPT (0.73) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL8211228 0.75 MAPT (0.73) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL8211222 0.75 MAPT (0.73) MAPTMEN1KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108677-A1 Thioxothiazolidinone Compounds For Use As Pharmaceuticals KARYON-CTT LTD (FI) 2008-05-08 US claimed
EP-1789406-A1 THIOXOTHIAZOLIDINONE COMPOUNDS FOR USE AS PHARMACEUTICALS Karyon-CTT Ltd (FI) 2007-05-30 EP claimed
WO-2006024699-A1 THIOXOTHIAZOLIDINONE COMPOUNDS FOR USE AS PHARMACEUTICALS KARYON-CTT LTD (FI) 2006-03-09 WO claimed
US-20080108677-A1 Thioxothiazolidinone Compounds For Use As Pharmaceuticals KARYON-CTT LTD (FI) 2008-05-08 US disclosed
EP-1789406-A1 THIOXOTHIAZOLIDINONE COMPOUNDS FOR USE AS PHARMACEUTICALS Karyon-CTT Ltd (FI) 2007-05-30 EP disclosed
WO-2006024699-A1 THIOXOTHIAZOLIDINONE COMPOUNDS FOR USE AS PHARMACEUTICALS KARYON-CTT LTD (FI) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108677-A1 Thioxothiazolidinone Compounds For Use As Pharmaceuticals ITGAM, ITGB1, ITGA1 MAPT 1926/4885MEN1 4099/4885KMT2A 2994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.